Brief: Captor Therapeutics Seeks NASDAQ Entry Under Strategic Plans Update

Captor Therapeutics SA

06/03/2023 17:25

March 6 (Reuters) - Captor Therapeutics SA  CTXP.WA :
    * APPROVES STRATEGIC PLANS FOR 2023-2025
    * SEES 2023-2025 TOTAL OPERATING COSTS AT ABOUT $79.4
MILLION
    * PLANS TO ISSUE UP TO 1.2 MILLION OF OWN SHARES TO SECURE
FUNDING
FOR ITS STRATEGIC PLANS
    * PLANS TO EXPAND KNOW-HOW IN AREA OF TARGETED PROTEIN
DEGRADATION
    * AS PART OF ITS KEY STRATEGIC PLANS, COMPANY INTENDS TO
BEGIN
CLINICAL TRIALS FOR CT-01 PROJECT IN 2023 AND IN 2024 FOR CT-03
    * PLANS TO USE CURRENT INVESTOR BASE TO ATTRACT FOREIGN
INVESTORS
WITH PARTICULAR FOCUS ON AMERICAN MARKET, WHICH MAY POTENTIALLY
TRANSLATE INTO COMPANY'S ENTRY ON NASDAQ STOCK EXCHANGE
    * INTENDS TO CONFIRM EFFECTIVENESS OF CT-02 AND CT-05
PROJECTS VIA
IN-VIVO PROOF OF EFFICACY STUDY IN 2023 AND BEGIN TALKS TO
COMMERCIALISE THESE PROJECTS
    * PLANS TO EXPAND OPTIGRADETM PLATFORM WITH NEW DEGRADERS
WITH
HIGH-POTENTIAL CLINICAL TRIALS

Source text for Eikon:  ID:nEM7Q00FKa 
Further company coverage:  CTXP.WA 

 (Reporting by Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com;))